Stockscreener 앱 받기
9.40
3.30%
0.30
시간 외 거래:
9.40
전일 마감가:
$9.10
열려 있는:
$9.2
하루 거래량:
283.58K
Relative Volume:
0.34
시가총액:
$213.03M
수익:
$146.07M
순이익/손실:
$-196.04M
주가수익비율:
-0.5655
EPS:
-16.621
순현금흐름:
$-75.37M
1주 성능:
+3.18%
1개월 성능:
+22.56%
6개월 성능:
+56.15%
1년 성능:
+115.35%
1일 변동 폭
$9.06
$9.83
1주일 범위
$8.958
$10.22
52주 변동 폭
$3.6503
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
9.40 | 218.47M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Rodman & Renshaw | Buy |
| 2026-02-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-10-13 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | 재개 | H.C. Wainwright | Buy |
| 2023-01-19 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | 개시 | Morgan Stanley | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-05 | 재확인 | Robert W. Baird | Outperform |
| 2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-02-28 | 재확인 | BofA/Merrill | Underperform |
| 2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | 개시 | B. Riley FBR | Buy |
| 2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-04-02 | 재개 | Leerink Partners | Outperform |
| 2017-11-15 | 재개 | H.C. Wainwright | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2016-09-08 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-08-18 | 개시 | H.C. Wainwright | Buy |
| 2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - TradingView
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - GlobeNewswire Inc.
Karyopharm Therapeutics secures EHA Congress acclaim for late-breaking SENTRY trial update - Traders Union
Cantor Fitzgerald reiterates Overweight on Karyopharm stock - Investing.com UK
Cantor Fitzgerald reiterates Overweight on Karyopharm stock By Investing.com - Investing.com South Africa
How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) - Yahoo Finance
T. Rowe Price (KPTI) files Schedule 13G/A showing 6.6% position - Stock Titan
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-06-02 - Seeking Alpha
KPTI: Karyopharm's Abstract Accepted for Presentation at Europea - GuruFocus
KPTI: Karyopharm Announces Positive Phase 3 SENTRY Trial Results - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm reports phase 3 myelofibrosis trial results at ASCO - Investing.com UK
Karyopharm reports phase 3 myelofibrosis trial results at ASCO By Investing.com - Investing.com Nigeria
Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm’s myelofibrosis trial selected for EHA presentation By Investing.com - Investing.com South Africa
Karyopharm’s myelofibrosis trial selected for EHA presentation - Investing.com UK
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - Karyopharm
Cancer trial suggests spleen shrinkage may predict survival in myelofibrosis - Stock Titan
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology - Karyopharm
Karyopharm Therapeutics Presents Results from Phase 3 Sentry Trial of Selinexor Plus Ruxolitinib in Myelofibrosis - marketscreener.com
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm
Karyopharm Therapeutics (KPTI) to Discuss SENTRY Trial Results i - GuruFocus
Karyopharm to host call on phase 3 myelofibrosis trial results By Investing.com - Investing.com Australia
Karyopharm to host call on phase 3 myelofibrosis trial results - Investing.com
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation - Karyopharm
Myelofibrosis Phase 3 trial data to be detailed on June 2 call - Stock Titan
KPTI Q1 2026 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock DipsQuarterly Profit Report - newsline.com
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
Karyopharm Therapeutics (KPTI) Holds Near $9.10 Amid Low-Volume ConsolidationPercent Below MA - newsline.com
KPTI News | KARYOPHARM THERAPEUTICS INC (NASDAQ:KPTI) - ChartMill
Karyopharm (NASDAQ: KPTI) boosts share plans and grants CEO PSU awards - Stock Titan
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference - Karyopharm
Karyopharm to Speak at 2026 Jefferies Global Healthcare Conference - Intellectia AI
Cancer drug maker Karyopharm joins 2026 Jefferies healthcare summit - Stock Titan
Wall Street Analysts Think Karyopharm Therapeutics (KPTI) Could Surge 70.46%: Read This Before Placing a Bet - Yahoo Finance
Karyopharm (KPTI) director Christy Oliger receives 15,508 RSU equity award - Stock Titan
Karyopharm (KPTI) director awarded 15,508 RSUs vesting in 2027 - Stock Titan
Chen Schor of Karyopharm (KPTI) receives 15,508 RSU award - Stock Titan
Karyopharm Therapeutics (KPTI) director receives 15,508 RSUs in equity award - Stock Titan
Karyopharm (KPTI) director receives 15,508 RSU equity award vesting in 2027 - Stock Titan
Karyopharm (NASDAQ: KPTI) director gets 15,508 RSUs vesting in 2027 - Stock Titan
Karyopharm Therapeutics spotlights selinexor milestones, ASCO data and cancer trial readouts - MSN
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts - Barchart
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Karyopharm Therapeutics Inc 주식 (KPTI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rangwala Reshma | EVP & Chief Medical Officer |
May 14 '26 |
Sale |
9.50 |
408 |
3,876 |
56,829 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer |
May 14 '26 |
Sale |
9.50 |
324 |
3,078 |
107,940 |
| Abate Kristin | Chief Accounting Officer |
May 14 '26 |
Sale |
9.50 |
53 |
504 |
23,801 |
| Paulson Richard A. | President and CEO |
May 14 '26 |
Sale |
9.50 |
2,203 |
20,928 |
269,747 |
| Mano Michael | EVP, CLO&Secretary |
May 14 '26 |
Sale |
9.50 |
266 |
2,527 |
94,398 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Apr 21 '26 |
Sale |
8.94 |
449 |
4,014 |
56,290 |
| Mano Michael | EVP, CLO&Secretary |
Mar 02 '26 |
Sale |
9.41 |
3,526 |
33,178 |
93,964 |
| Rangwala Reshma | EVP & Chief Medical Officer |
Mar 02 '26 |
Sale |
9.41 |
5,066 |
47,669 |
56,739 |
| Paulson Richard A. | President and CEO |
Mar 02 '26 |
Sale |
9.41 |
12,361 |
116,311 |
267,030 |
| Poulton Stuart | EVP, Chief Development Officer |
Feb 17 '26 |
Sale |
8.63 |
378 |
3,262 |
99,429 |
2.60%
0.94%
자본화:
|
볼륨(24시간):